MCID: PRR013
MIFTS: 38

Prurigo Nodularis

Categories: Rare diseases, Skin diseases

Aliases & Classifications for Prurigo Nodularis

MalaCards integrated aliases for Prurigo Nodularis:

Name: Prurigo Nodularis 53 55 72 33
Nodular Prurigo 53

Classifications:



External Ids:

ICD10 33 L28.1
UMLS 72 C0263353

Summaries for Prurigo Nodularis

NIH Rare Diseases : 53 Prurigo nodularis (PN) is a skin disease that causes hard, itchy lumps (nodules) to form on the skin. The itching (pruritus) can be intense, causing people to scratch themselves to the point of bleeding or pain. Scratching can cause more skin lesions to appear. The itching is worsened by heat, sweating, or irritation from clothing. In some cases, people with PN have a history of other diseases including eczema (atopic dermatitis), lymphoma, HIV infection, severe anemia, or kidney disease. The exact cause of PN is unknown. Although scratching is known to cause more nodules to appear, it is unclear what causes the itching to develop in the first place. Diagnosis of the disease is based on observing signs such as extremely itchy skin with the formation of nodules. In some cases, a skin biopsy is used to confirm the diagnosis. Treatment may include corticosteroid creams, oral medications, cryotherapy, or photochemotherapy.

MalaCards based summary : Prurigo Nodularis, also known as nodular prurigo, is related to peripheral nervous system disease and anhidrosis. An important gene associated with Prurigo Nodularis is RNASE3 (Ribonuclease A Family Member 3), and among its related pathways/superpathways are Phospholipase-C Pathway and p70S6K Signaling. The drugs Nalbuphine and Serlopitant have been mentioned in the context of this disorder. Affiliated tissues include skin, kidney and t cells.

Wikipedia : 75 Prurigo nodularis (PN), also known as nodular prurigo, is a skin disease characterised by pruritic... more...

Related Diseases for Prurigo Nodularis

Diseases related to Prurigo Nodularis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 134)
# Related Disease Score Top Affiliating Genes
1 peripheral nervous system disease 30.2 TAC1 NGF
2 anhidrosis 30.1 NGFR NGF
3 amyloidosis, primary localized cutaneous, 1 11.4
4 epidermolysis bullosa pruriginosa 11.4
5 amyloidosis, primary localized cutaneous, 2 11.4
6 amyloidosis, primary localized cutaneous, 3 11.4
7 skin disease 10.7
8 dermatitis, atopic 10.6
9 dermatitis 10.6
10 neuropathy 10.6
11 neurodermatitis 10.5
12 bullous pemphigoid 10.5
13 keratosis 10.4
14 vitiligo-associated multiple autoimmune disease susceptibility 6 10.4
15 vitiligo-associated multiple autoimmune disease susceptibility 1 10.4
16 lymphoma 10.4
17 contact dermatitis 10.4
18 chronic kidney disease 10.4
19 lichen planus 10.4
20 hypereosinophilic syndrome 10.4
21 ige responsiveness, atopic 10.3
22 lymphoma, hodgkin, classic 10.3
23 pulmonary alveolar microlithiasis 10.3
24 human immunodeficiency virus type 1 10.3
25 exanthem 10.3
26 allergic hypersensitivity disease 10.3
27 neuroma 10.3
28 hepatitis 10.3
29 allergic contact dermatitis 10.3
30 keratoacanthoma 10.3
31 uremia 10.3
32 scabies 10.3
33 herpes zoster 10.3
34 vasculitis 10.3
35 vasomotor rhinitis 10.2 TAC1 RNASE3
36 erythermalgia, primary 10.1
37 hashimoto thyroiditis 10.1
38 systemic lupus erythematosus 10.1
39 pernicious anemia 10.1
40 sarcoidosis 1 10.1
41 thrombocytopenic purpura, autoimmune 10.1
42 celiac disease 1 10.1
43 immune deficiency disease 10.1
44 myeloma, multiple 10.1
45 proteasome-associated autoinflammatory syndrome 1 10.1
46 dermatitis herpetiformis, familial 10.1
47 becker nevus syndrome 10.1
48 lymphoma, non-hodgkin, familial 10.1
49 pulmonary disease, chronic obstructive 10.1
50 nasopharyngeal carcinoma 10.1

Graphical network of the top 20 diseases related to Prurigo Nodularis:



Diseases related to Prurigo Nodularis

Symptoms & Phenotypes for Prurigo Nodularis

Drugs & Therapeutics for Prurigo Nodularis

Drugs for Prurigo Nodularis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 57)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nalbuphine Approved Phase 2, Phase 3 20594-83-6 5360630 5311304
2 Serlopitant Investigational Phase 3 860642-69-9
3 neurokinin A Phase 3
4 Neurokinin-1 Receptor Antagonists Phase 3
5
Substance P Phase 3 33507-63-0 44359816
6 Neurotransmitter Agents Phase 3
7 Peripheral Nervous System Agents Phase 2, Phase 3
8 Analgesics Phase 2, Phase 3
9 Narcotics Phase 2, Phase 3
10 Central Nervous System Depressants Phase 2, Phase 3
11 Analgesics, Opioid Phase 2, Phase 3
12
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492 6473866
13
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754
14
Hydrocortisone acetate Approved, Vet_approved Phase 2 50-03-3
15
Pimecrolimus Approved, Investigational Phase 2 137071-32-0 17753757 6447131
16
Apremilast Approved, Investigational Phase 1, Phase 2 608141-41-9 11561674
17 Hydrocortisone-17-butyrate Phase 2
18 Hydrocortisone 17-butyrate 21-propionate Phase 2
19 Hydrocortisone hemisuccinate Phase 2
20 Calcineurin Inhibitors Phase 2
21 Pharmaceutical Solutions Phase 2
22 Antipruritics Phase 1, Phase 2
23 Anti-Infective Agents Phase 1, Phase 2
24 Anti-Bacterial Agents Phase 1, Phase 2
25 Anti-Inflammatory Agents Phase 1, Phase 2
26 Immunologic Factors Phase 1, Phase 2
27 Analgesics, Non-Narcotic Phase 1, Phase 2
28 Angiogenesis Inhibitors Phase 1, Phase 2
29 Anti-Inflammatory Agents, Non-Steroidal Phase 1, Phase 2
30 Angiogenesis Modulating Agents Phase 1, Phase 2
31 Immunosuppressive Agents Phase 1, Phase 2
32 Antirheumatic Agents Phase 1, Phase 2
33 Dermatologic Agents Phase 1, Phase 2
34
Citalopram Approved 59729-33-8 2771
35
leucovorin Approved 58-05-9 143 6006
36
Dapsone Approved, Investigational 80-08-0 2955
37
Folic acid Approved, Nutraceutical, Vet_approved 59-30-3 6037
38 Serotonin Uptake Inhibitors
39 Parasympatholytics
40 Antidepressive Agents
41 Antidepressive Agents, Second-Generation
42 Neurotransmitter Uptake Inhibitors
43 Cholinergic Agents
44 Muscarinic Antagonists
45 Serotonin Agents
46 Cholinergic Antagonists
47 Psychotropic Drugs
48 Antiparkinson Agents
49 Autonomic Agents
50 Folic Acid Antagonists

Interventional clinical trials:

(show all 13)
# Name Status NCT ID Phase Drugs
1 A Randomized, Double-Blind, Placebo-Controlled, Parallel, 3-Arm Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Prurigo Nodularis Patients Completed NCT02174419 Phase 2, Phase 3 nalbuphine HCl ER tablets 90 mg BID;nalbuphine HCl ER tablets 180 mg BID;Placebo tablets BID
2 An Open Label Extension Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Prurigo Nodularis Patients Completed NCT02174432 Phase 2, Phase 3 nalbuphine HCl ER 90 mg BID;nalbuphine HCl ER 120 mg BID;nalbuphine HCl ER 180 mg BID
3 A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritus in Adults With Prurigo Nodularis Recruiting NCT03546816 Phase 3 5mg Serlopitant Tablets;Placebo Tablets
4 A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritus in Adults With Prurigo Nodularis Recruiting NCT03677401 Phase 3 5mg Serlopitant Tablets;Placebo Tablets
5 A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 2-Arm , Efficacy and Safety Study in Prurigo Nodularis (PN) With Nalbuphine ER Tablets for Pruritus Relief Through Itch Scratch Modulation (PRISM Study) Recruiting NCT03497975 Phase 2, Phase 3 Nalbuphine ER Tablets
6 A Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis (PN) Completed NCT03181503 Phase 2 CD14152 Dose A;CD14152 placebo
7 A Randomized, Double-Blind, Placebo-Controlled, Study of Neurokinin-1 Receptor Antagonist Serlopitant in Subjects With Prurigo Nodularis Completed NCT02196324 Phase 2 serlopitant;Placebo
8 An Open Label, Single Center Study to Assess the Safety and Efficacy of a 24 Week Treatment Course of CC-10004 in Adults With Recalcitrant Nodularis Completed NCT00869089 Phase 2 CC-10004
9 Evaluation of the Antipruritic Effect of Elidel (Pimecrolimus) in Non-atopic Pruritic Disease Completed NCT00507832 Phase 2 Pimecrolimus;Hydrocortisone;Pimecrolimus
10 A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritus in Subjects With Prurigo Nodularis Recruiting NCT03816891 Phase 2 KPL-716;Placebo
11 Apremilast as Anti-pruritic Treatment in Patients With Prurigo Nodularis Recruiting NCT03576287 Phase 1, Phase 2 Apremilast Oral Product
12 Effectiveness of the Selective Serotonin Reuptake Inhibitor,Citalopram (Cipralex), in Prurigo Nodularis Unknown status NCT00532519 citalopram (cipralex)
13 A Double-blind, Randomized, Parallel-group, Side-by-side Single-center Study Comparing a Topical Steroid / Vehicle Combination to a Topical Steroid / Topical Dapsone Combination in Patients With Lichen Simplex Chronicus and/or Prurigo Nodularis Not yet recruiting NCT01870050 Dapsone gel - verum

Search NIH Clinical Center for Prurigo Nodularis

Genetic Tests for Prurigo Nodularis

Anatomical Context for Prurigo Nodularis

MalaCards organs/tissues related to Prurigo Nodularis:

41
Skin, Kidney, T Cells, Tonsil, Brain, Liver, Thyroid

Publications for Prurigo Nodularis

Articles related to Prurigo Nodularis:

(show top 50) (show all 500)
# Title Authors PMID Year
1
Psychiatric disorders and pruritus. 38 6
28511824 2017
2
Treatment of prurigo nodularis with lenalidomide. 38 6
27891738 2017
3
Increased nerve growth factor- and tyrosine kinase A-like immunoreactivities in prurigo nodularis skin -- an exploration of the cause of neurohyperplasia. 9 38
11875644 2002
4
Eosinophil cationic protein- and eosinophil-derived neurotoxin/eosinophil protein X-immunoreactive eosinophils in prurigo nodularis. 9 38
10994770 2000
5
Histamine-containing mast cells and their relationship to NGFr-immunoreactive nerves in prurigo nodularis: a reappraisal. 9 38
9609137 1998
6
Eosinophilic cationic protein (ECP) in skin disorders. 9 38
1685831 1991
7
Prurigo nodularis as a sweat gland/duct-related disorder: resolution associated with restoration of sweating disturbance. 38
31152230 2019
8
Dupilumab after the 2017 approval for the treatment of atopic dermatitis: what's new and what's next? 38
31145194 2019
9
[Pruritus in systemic diseases : Common and rare etiologies]. 38
31243493 2019
10
Real-world prevalence of prurigo nodularis and burden of associated diseases. 38
31421126 2019
11
Dramatic improvement of generalized prurigo nodularis with dupilumab. 38
30893496 2019
12
Inpatient Burden of Prurigo Nodularis in the United States. 38
31405223 2019
13
The NK1 receptor antagonist serlopitant for treatment of chronic pruritus. 38
31272246 2019
14
Diagnostic and Treatment Algorithm for Chronic Nodular Prurigo. 38
31310842 2019
15
Fibreglass dermatitis in a caravan manufacturer manifesting as prurigo nodularis. 38
31177543 2019
16
Use of Dupilumab in HIV-positive Patients: Report of Four Cases. 38
31206599 2019
17
Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial. 38
30894279 2019
18
An observational analysis of low-dose thalidomide in recalcitrant prurigo nodularis. 38
31132160 2019
19
Aberrant Expression of Histamine-independent Pruritogenic Mediators in Keratinocytes may be Involved in the Pathogenesis of Prurigo Nodularis. 38
30809683 2019
20
Recalcitrant prurigo nodularis treated successfully with dupilumab. 38
31192991 2019
21
Association between prurigo nodularis and malignancy in middle-aged adults. 38
30954580 2019
22
Aprepitant in Anti-histamine-refractory Chronic Nodular Prurigo: A Multicentre, Randomized, Double-blind, Placebo-controlled, Cross-over, Phase-II trial (APREPRU). 38
30653242 2019
23
Corticosteroid-resistant prurigo nodularis: a rare syringotropic variant associated with hypohidrosis. 38
30827950 2019
24
Allergic contact dermatitis caused by chloramphenicol with prurigo nodularis-like spreading. 38
30485440 2019
25
Inflammatory mediators causing cutaneous chronic itch in some diseases via transient receptor potential channel subfamily V member 1 and subfamily A member 1. 38
30588658 2019
26
A systematic review of evidence-based treatments for prurigo nodularis. 38
30261199 2019
27
Prurigo nodularis and pembrolizumab: A therapeutic challenge. 38
30735833 2019
28
Dermatoscopic Features of Prurigo Nodularis. 38
30984602 2019
29
[Unprecedented interest in prurigo nodularis]. 38
30691876 2019
30
A systematic review and meta-analysis of the regional and age-related differences in atopic dermatitis clinical characteristics. 38
30287309 2019
31
Hyperpigmentation Due to Cyclosporine Therapy. 38
31019850 2019
32
Utility of Naltrexone Treatment for Chronic Inflammatory Dermatologic Conditions: A Systematic Review. 38
30484835 2019
33
Pemphigoid nodularis - rare presentation of bullous pemphigoid: A case report and literature review. 38
30679985 2019
34
Whole exome sequencing identified two point mutations of COL7A1 and FLG in a Chinese family with dystrophic epidermolysis bullous pruriginosa and ichthyosis vulgaris. 38
30549102 2019
35
Treatment-resistant prurigo nodularis: challenges and solutions. 38
30881076 2019
36
Dupilumab Treatment for Generalized Prurigo Nodularis. 38
30427994 2019
37
Treatment-resistant prurigo nodularis. 38
31190941 2019
38
Distinguishing truly recalcitrant prurigo nodularis from poor treatment adherence: a response to treatment-resistant prurigo nodularis [Response to letter]. 38
31190945 2019
39
Reduced Itch Associated With Dupilumab Treatment In 4 Patients With Prurigo Nodularis. 38
30427989 2019
40
Efficacy and Safety of Fire Needle Therapy for Nodular Prurigo: A Quantitative Study. 38
31341502 2019
41
Prurigo nodularis: a physician survey to evaluate current perceptions of its classification, clinical experience and unmet need. 38
29869425 2018
42
[Kaposi sarcoma in a patient with ANCA vasculitis requiring hemodialysis]. 38
30316478 2018
43
Use of antiepileptic mood stabilizers in dermatology. 38
30446200 2018
44
Ethnic differences and comorbidities of 909 prurigo nodularis patients. 38
29733939 2018
45
Clinical characteristics and genetic variation in atopic dermatitis patients with and without allergic contact dermatitis. 38
30530433 2018
46
Comprehending prurigo nodularis: Ay, there's the rub. 38
30092325 2018
47
Xerosis cutis and associated co-factors in women with prurigo nodularis. 38
30156616 2018
48
Humanistic burden of chronic pruritus in patients with inflammatory dermatoses: Results of the European Academy of Dermatology and Venereology Network on Assessment of Severity and Burden of Pruritus (PruNet) cross-sectional trial. 38
30119869 2018
49
The Prevalence of Psychiatric Comorbidity in Patients with Prurigo Nodularis. 38
30258799 2018
50
Itching at night: A review on reducing nocturnal pruritus in children. 38
29943835 2018

Variations for Prurigo Nodularis

Expression for Prurigo Nodularis

Search GEO for disease gene expression data for Prurigo Nodularis.

Pathways for Prurigo Nodularis

Pathways related to Prurigo Nodularis according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.55 SEMA3A NGFR NGF
2
Show member pathways
12.52 SEMA3A NGFR NGF
3
Show member pathways
12.12 SEMA3A NGFR NGF
4 11.73 TAC1 NGF
5
Show member pathways
11.69 NGFR NGF
6 11.65 NGFR NGF
7
Show member pathways
11.54 SEMA3A NGFR NGF
8
Show member pathways
11.45 SEMA3A NGFR NGF
9
Show member pathways
11.3 NGFR NGF
10
Show member pathways
11.22 NGFR NGF
11
Show member pathways
11.15 NGFR NGF
12 10.87 SEMA3A NGFR NGF
13 10.46 NGFR NGF

GO Terms for Prurigo Nodularis

Cellular components related to Prurigo Nodularis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.46 TAC1 SEMA3A RNASE3 NGF
2 axon GO:0030424 9.13 TAC1 SEMA3A NGF
3 extracellular region GO:0005576 9.02 TAC1 SEMA3A RNASE3 NGFR NGF

Biological processes related to Prurigo Nodularis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.4 NGFR NGF
2 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 9.37 NGFR NGF
3 positive regulation of axonogenesis GO:0050772 9.26 NGFR NGF
4 neurotrophin TRK receptor signaling pathway GO:0048011 9.16 NGFR NGF
5 negative regulation of neuron projection development GO:0010977 9.02 SEMA3A
6 nerve development GO:0021675 8.96 SEMA3A NGF
7 regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043281 8.62 NGFR NGF

Sources for Prurigo Nodularis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....